Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) FCF Margin (2016 - 2026)

United Therapeutics' FCF Margin history spans 17 years, with the latest figure at 21.93% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1265.0% to 21.93% in Q4 2025 year-over-year; TTM through Dec 2025 was 32.7%, a 486.0% decrease, with the full-year FY2025 number at 32.7%, down 486.0% from a year prior.
  • FCF Margin hit 21.93% in Q4 2025 for United Therapeutics, down from 43.98% in the prior quarter.
  • Over the last five years, FCF Margin for UTHR hit a ceiling of 65.79% in Q1 2023 and a floor of 7.3% in Q4 2023.
  • Historically, FCF Margin has averaged 35.98% across 5 years, with a median of 35.91% in 2024.
  • Biggest five-year swings in FCF Margin: tumbled -5064bps in 2023 and later skyrocketed 4189bps in 2024.
  • Tracing UTHR's FCF Margin over 5 years: stood at 53.25% in 2021, then fell by -19bps to 43.34% in 2022, then plummeted by -117bps to 7.3% in 2023, then skyrocketed by 573bps to 34.58% in 2024, then tumbled by -37bps to 21.93% in 2025.
  • Business Quant data shows FCF Margin for UTHR at 21.93% in Q4 2025, 43.98% in Q3 2025, and 16.22% in Q2 2025.